Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020538 (
hypertension
)
170,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
WNK1
is a serine-threonine kinase, the expression of which is affected in pseudohypoaldosteronism type II, a Mendelian form of arterial
hypertension
. We characterized human
WNK1
transcripts to determine the molecular mechanisms governing
WNK1
expression. We report the presence of two promoters generating two
WNK1
isoforms with a complete kinase domain. Further variations are achieved by the use of two polyadenylation sites and tissue-specific splicing. We also determined the structure of a kidney-specific isoform regulated by a third promoter and starting at a novel exon. This transcript is kinase defective and has a predominant expression in the kidney compared to the other
WNK1
isoforms, with, furthermore, a highly restricted expression profile in the distal convoluted tubule. We confirmed that the ubiquitous and kidney-specific promoters are functional in several cells lines and identified core promoters and regulatory elements. In particular, a strong enhancer element upstream from the kidney-specific exon seems specific to renal epithelial cells. Thus, control of human
WNK1
gene expression of kinase-active or -deficient isoforms is mediated predominantly through the use of multiple transcription initiation sites and tissue-specific regulatory elements.
...
PMID:Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. 1464 31
WNK1
belongs to a unique protein kinase family that lacks the catalytic lysine in its normal position. Mutations in human
WNK1
and WNK4 have been implicated in causing a familial form of
hypertension
. Here we report that overexpression of
WNK1
led to increased activity of cotransfected ERK5 in HEK293 cells. ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant negative MEK5 mutant. Expression of dominant negative mutants of MEKK2 and MEKK3 also blocked activation of ERK5 by
WNK1
. Moreover, both MEKK2 and MEKK3 coimmunoprecipitated with endogenous
WNK1
from cell lysates.
WNK1
phosphorylated both MEKK2 and -3 in vitro, and MEKK3 was activated by
WNK1
in 293 cells. Finally, ERK5 activation by epidermal growth factor was attenuated by suppression of
WNK1
expression using small interfering RNA. Taken together, these results place
WNK1
in the ERK5 MAP kinase pathway upstream of MEKK2/3.
...
PMID:WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. 1468 Dec 16
WNK kinases are novel serine/threonine protein kinases. Mutations in two members of the WNK family,
WNK1
and WNK4, cause familial hyperkalemic
hypertension
. These kinases regulate ion transport across diverse epithelia; WNK4 reduces activity of the Na-Cl cotransporter activity and the potassium channel, ROMK, by reducing their appearance at the plasma membrane. We examined the kinase activity of
WNK1
and WNK4 in vitro. A glutathione S-transferase (GST) fusion protein of the
WNK1
kinse domain phosphorylated itself and a substrate protein, as reported previously. A longer construct, containing the autoinhibitory domain, did not. A GST WNK4 kinase domain construct demonstrated no kinase activity, in vitro or in HEK 293 cells. WNK4 constructs that included a region homologous to the autoinhibitory domain of
WNK1
inhibited
WNK1
kinase activity. Inhibition by a short WNK4 segment, WNK4 (444-518), was greater than inhibition by WNK4 (444-563). Together, these results suggest that WNK4 must be activated by currently unknown factors to exhibit kinase activity and that WNK4 contains an inhibitory domain that can inhibit the kinase activity of
WNK1
.
...
PMID:Comparison of WNK4 and WNK1 kinase and inhibiting activities. 1508 30
WNK kinases comprise a small group of unique serine/threonine protein kinases that have been genetically linked to pseudohypoaldosteronism type II, an autosomal dominant form of
hypertension
. Here we present the structure of the kinase domain of
WNK1
at 1.8 A resolution, solved in a low activity conformation. A lysine residue (Lys-233) is found in the active site emanating from strand beta2 rather than strand beta3 as in other protein kinases. The activation loop adopts a unique well-folded inactive conformation. The conformations of the P+1 specificity pocket, the placement of the conserved active site threonine (Thr-386), and the exterior placement of helix C, contribute to the low activity state. By homology modeling, we identified two hydrophobic residues in the substrate-binding groove that contribute to substrate specificity. The structure of the
WNK1
catalytic domain, with its unique active site, may help in the design of therapeutic reagents for the treatment of
hypertension
.
...
PMID:Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. 1524 6
Familial hyperkalemia and
hypertension
(FHH; pseudohypoaldosteronism type II) is an autosomal dominant disorder characterized by hyperkalemia,
hypertension
, and low renin.
WNK1
kinase overexpression and WNK4 kinase inactivating missense mutations cause FHH. When expressed in frog oocyte, WNK4 inhibits Na-Cl cotransporter surface expression, and
WNK1
relieves this inhibition. We have reported hypercalciuria in subjects with the WNK4 Q565E mutation. In contrast, in subjects with
WNK1
overexpression, normocalciuria was found. Here we report a major extension of our previously described kindred that contains 34 subjects, 18 of them affected by the mutation.
Hypertension
was diagnosed in 13 affected subjects at the age of 31 +/- 12 yr. Five of the affected or obligatory affected subjects had stroke, in four at the age of 50-62 yr. Seven subjects with FHH were diagnosed 27 yr previously. All four subjects who were normotensive at diagnosis became hypertensive during follow-up. The mean time between detection of hyperkalemia and appearance of
hypertension
was 13 yr. In the extended kindred, compared with the unaffected subjects, affected subjects had hyperkalemia, low transtubular potassium gradient, hyperchloremia, low bicarbonate, higher aldosterone, and marked suppression of renin. Urinary calcium levels in affected and unaffected subjects were 0.85 +/- 0.27 and 0.28 +/- 0.12 mmol/mmol creatinine, respectively (P < 0.0001). Hypercalciuria was accompanied by lower serum calcium levels [9.44 +/- 0.15 vs. 9.81 +/- 0.31 mg/dl (2.36 +/- 0.04 vs. 2.45 +/- 0.08 mmol/liter); P = 0.01], supporting a mechanism of renal calcium leak. The six affected, currently normotensive subjects had the same degree of hyperkalemia, hypercalciuria, and low renin as the affected hypertensive subjects. We conclude that in FHH with WNK4 mutations, with time all affected subjects will apparently develop
hypertension
. Hypercalciuria accompanies hyperkalemia, and both precede
hypertension
. Based on the recent findings that WNK4 regulates the renal outer medullary potassium channel as well as epithelial Cl(-)/base exchanger and the Na(+)-K(+)-2Cl(-) cotransporter, we suggest that WNK4 interacts with a calcium channel or transporter.
...
PMID:Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. 1529 44
The deletion of thiazide-sensitive Na-Cl cotransporter ( TSC, SLC12A3) causes Gitelman's syndrome characterized by low blood pressure, while deletions of the
WNK1
( PRKWNK1) and WNK4 ( PRKWNK4) genes cause familial hypertension known as pseudohypoaldosteronism type II. Recent studies have revealed that cell surface expression of TSC is regulated by
WNK1
and WNK4. We hypothesized that molecular variations in TSC,
WNK1
, and WNK4 could lead to an increased morbidity of
hypertension
. We identified 52, 35, and 21 polymorphisms in Japanese hypertensives by sequencing the entire coding regions of TSC,
WNK1
and WNK4, respectively. Twenty-one representative polymorphisms were genotyped in 1,818 Japanese individuals (771 subjects with
hypertension
and 1,047 controls) randomly sampled in Suita city. The results indicated that the systolic blood pressure in men with the CT+TT genotype in WNK4 C14717T was 3.1 mmHg higher than those with the CC genotype ( p=0.042) after adjustment with confounding factors such as age, BMI, hyperlipidemia, diabetes mellitus, antihypertensive drug use, smoking, and drinking. Multivariate logistic regression analysis (with adjustment for the same parameters) in men revealed that the odds ratio for the presence of
hypertension
of the CT+TT genotype in C14717T to the CC genotype was 1.62 ( p=0.010, 95% confidence interval, 1.12-2.33). Association of TSC and
WNK1
with
hypertension
was not observed. In conclusion, our study suggests the possible involvement of WNK4 in essential hypertension in a Japanese general population.
...
PMID:Identification of 108 SNPs in TSC, WNK1, and WNK4 and their association with hypertension in a Japanese general population. 1530 83
WNK (with no lysine [K]) protein kinases were named for their unique active site organization. Mutations in
WNK1
and WNK4 cause a familial form of
hypertension
by undefined mechanisms. Here, we report that
WNK1
selectively binds to and phosphorylates synaptotagmin 2 (Syt2) within its calcium binding C2 domains. Endogenous
WNK1
and Syt2 coimmunoprecipitate and colocalize on a subset of secretory granules in INS-1 cells. Phosphorylation by
WNK1
increases the amount of Ca2+ required for Syt2 binding to phospholipid vesicles; mutation of threonine 202, a
WNK1
phosphorylation site, partially prevents this change. These findings suggest that phosphorylation of Syts by
WNK1
can regulate Ca2+ sensing and the subsequent Ca2+-dependent interactions mediated by Syt C2 domains. These findings provide a biochemical mechanism that could lead to the retention or insertion of proteins in the plasma membrane. Interruption of this regulatory pathway may disturb membrane events that regulate ion balance.
...
PMID:WNK1 phosphorylates synaptotagmin 2 and modulates its membrane binding. 1535 Feb 18
WNK1
belongs to a unique family of Ser/Thr kinases that have been implicated in the control of blood pressure. Intronic deletions in the
WNK1
gene result in its overexpression and lead to pseudohypoaldosteronism type II, a disease with salt-sensitive
hypertension
and hyperkalemia. How overexpression of
WNK1
leads to Na(+) retention and
hypertension
is not entirely clear. Similarly, there is no information on the hormonal regulation of expression of WNK kinases. There are two main
WNK1
transcripts expressed in the kidney: the originally described "long"
WNK1
and a shorter transcript that is specifically expressed in the kidney (KS-
WNK1
). The goal of this study was to determine the effect of aldosterone, the main hormonal regulator of Na(+) homeostasis, on the transcription of
WNK1
isoforms in renal target cells, by using an unique mouse cortical collecting duct cell line that stably expresses functional mineralocorticoid receptors. Our results demonstrate that aldosterone, at physiological concentrations, rapidly induces the expression of the KS-
WNK1
but not that of the long-
WNK1
in these cells. Importantly, stable overexpression of KS-
WNK1
significantly increases transepithelial Na(+) transport in cortical collecting duct cells. Similarly, coexpression of KS-
WNK1
and the epithelial Na(+) channel in Fischer rat thyroid epithelial cells also stimulates Na(+) current, suggesting that KS-
WNK1
affects the subcellular location or activity but not the expression of epithelial Na(+) channel. These observations suggest that stimulation of KS-
WNK1
expression might be an important element of aldosterone-induced Na(+) retention and
hypertension
.
...
PMID:The kidney-specific WNK1 isoform is induced by aldosterone and stimulates epithelial sodium channel-mediated Na+ transport. 1558 31
A recently discovered family of protein kinases is responsible for an autosomal-dominant disease known as Gordon's syndrome or pseudohypoaldosteronism type II (PHA-II) that features hyperkalemia and hyperchloremic metabolic acidosis, accompanied by
hypertension
and hypercalciuria. Four genes have been described in this kinase family, which has been named WNK, due to the absence of a key lysine in kinase subdomain II (with no K kinases). Two of these genes,
WNK1
and WNK4 located in human chromosomes 12 and 17, respectively, are responsible for PHA-II. Immunohystochemical analysis revealed that
WNK1
and WNK4 are predominantly expressed in the distal convoluted tubule and collecting duct. The physiological studies have shown that WNK4 downregulates the activity of ion transport pathways expressed in these nephron segments, such as the apical thiazide-sensitive Na+-Cl- cotransporter and apical secretory K+ channel ROMK, as well as upregulates paracellular chloride transport and phosphorylation of tight junction proteins such as claudins. In addition, WNK4 downregulates other Cl- influx pathways such as the basolateral Na+-K+-2Cl- cotransporter and Cl-/HCO3- exchanger. WNK4 mutations behave as a loss of function for the Na+-Cl- cotransporter and a gain of function when it comes to ROMK and claudins. These dual effects of WNK4 mutations fit with proposed mechanisms for developing electrolyte abnormalities and
hypertension
in PHA-II and point to WNK4 as a multifunctional regulator of diverse ion transporters.
...
PMID:Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension. 1563 47
Arterial
hypertension
is a complex trait influenced by a variety of environmental and genetic factors. Several approaches can be used to identify its susceptibility genes : one is to study rare monogenic forms of
hypertension
, like familial hyperkalemic
hypertension
(FHH). Also known as pseudohypoaldosteronism type 2 or Gordon syndrome, FHH is characterized by
hypertension
, hyperkalemia despite normal renal glomerular filtration rate, abnormalities which are particularly sensitive to thiazide diuretics. Mild hyperchloremia, metabolic acidosis, and suppressed plasma renin activity are associated findings. Despite its phenotypic and genetic heterogeneity, mutations in two related genes,
WNK1
and WNK4, were recently identified. These genes belong to a newly identified family of serine-threonine (with no lysine [K]) kinases. Both are highly expressed in the kidney and in a variety of epithelia involved in chloride transport. It has thus been postulated that these two kinases could be implicated in a new pathway of ionic transport regulation. Several studies have very recently confirmed this hypothesis in vitro, in Xenopus oocytes or kidney cell lines. They have shown that, in the renal distal tubule, WNK4 inhibits sodium reabsorption and potassium secretion, via inhibition of NCC (thiazide-sensitive Na+-Cl- cotransporter) and K+ channel ROMK activity, respectively. Interestingly, FHH mutations have opposite effects : while they lead to loss of NCC inhibition, they increase ROMK inhibition. Moreover, they also increase paracellular permeability to chloride of MDCK cells. WNK4 also inhibits apical and basal chloride transporters present in extra-renal epithelia, such as CFEX and Na+-K+-2 Cl-, respectively. It is also interesting to note that the WNK4-mediated negative regulation of NCC activity is in turn inhibited by
WNK1
. By its role on several transporters, WNK4 appears as a putative key regulator of ionic transport and blood pressure.
...
PMID:[WNK1 and WNK4, new players in salt and water homeostasis]. 1563 21
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>